Docetaxel: A tubulin-stabilizing agent approved for the management of several solid tumors

Drugs of Today

Volumn 42, Issue 4, 2006, Pages 265-279

  Ramaswamy, Bhuvaneswari ^a   Puhalla, Shannon ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROMYCIN; ESTRAMUSTINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; KETOCONAZOLE; METHOTREXATE; MITOMYCIN; NAVELBINE; ORPHENADRINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; TARIQUIDAR; TRASTUZUMAB; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; EDEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; HAND FOOT SYNDROME; HUMAN; LACRIMATION DISORDER; LUNG CANCER; NAIL DYSTROPHY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TOXICITY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TUBULIN MODULATORS;

EID: 33745168280     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.4.968648     Document Type: Review

References (76)

1. Taxotere prescribing information. Aventis Pharmaceuticals Inc., Bridgewater, NJ 2004.
2. Bissery, M.C., Nohynek, G., Sanderink, G.J. et al. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995, 6: 339-55, 363-8.
3. Ringel, I., Horwitz, S.B. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 1991, 83: 288-91.
4. Michaud, L.B., Valero, V., Hortobagyi, G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000, 23: 401-28.
5. Valero, V., Jones, S.E., Von Hoff, D.D. et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998, 16: 3362-8.
6. Verschraegen, C.F., Sittisomwong, T., Kudelka, A.P. et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000, 18: 2733-9.
7. Valero, V., Holmes, F.A., Walters, R.S. et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13: 2886-94.
8. Ravdin, P.M., Burris, H.A. 3rd, Cook, G. et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995, 13: 2879-85.
9. Fossella, F., Pereira, J.R., von Pawel, J. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003, 21: 3016-24.
10. Tannock, I.F., de Wit, R., Berry, W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351: 1502-12.
11. Petrylak, D.P., Tangen, C.M., Hussain, M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351: 1513-20.
12. Eisenhauer, E., Vermorken, J.B. The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55: 5-30.
13. Diaz, J., Andreu, J.M. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32: 2747-55.
14. Bruno, R., Hille, D., Riva, A. et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998, 16: 187-96.
15. Bruno, R., Vivier, N., Veyrat-Follet, C. et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001, 19: 163-9.
16. Lockhart, A., Tirona, G., Kim, B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Ther 2003, 2: 695.
17. Fojo, A.T., Menefee, M. Microtubule targeting agents: Basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32 (6 Suppl. 7): S3-S8.
18. Lee, J.J., Swain, S.M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32 (6 Suppl. 7): S22-S26.
19. Pusztai, L., Wagner, P., Ibrahim, N. et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104: 682-91.
20. Shalli, K., Brown, I., Heys, S.D. et al. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. Faseb J 2005, 19: 1299-301.
21. Cortes, J.E., Pazdur, R. Docetaxel. J Clin Oncol 1995, 13: 2643-55.
22. Schrijvers, D., Wanders, J., Dirix, L. et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993, 4: 610-1.
23. Markman, M. Managing Taxane toxicities. Support Care Cancer 2003, 11: 144.
24. Piccart, M.J., Klijn, J., Paridaens, R. et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997, 15: 3149-55.
25. Zimmerman, G.C., Keeling, J.H., Burris, H.A. et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995, 131: 202-6.
26. Zimmerman, G.C., Keeling, J.H., Lowry, M. et al. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 1994, 86: 557-8.
27. Hainsworth, J.D., Burris, H.A. 3rd, Greco, F.A. Weekly administration of docetaxel (Taxotere): Summary of clinical data. Semin Oncol 1999, 26 (3 Suppl. 10): 19-24.
28. Esmaeli, B., Hortobagyi, G., Esteva, F. et al. Canalicular stenosis secondary to weekly docetaxel: A potentially preventable side effect. Ann Oncol 2002, 13: 218-21.
29. Esmaeli, B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer 2005, 5: 455-7.
30. Greco, F.A. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999, 26 (3 Suppl. 11): 28-31.
31. Burstein, H.J., Manola, J., Younger, J. et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18: 1212-9.
32. Beer, T.M., Pierce, W.C., Lowe, B.A. et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001, 12: 1273-9.
33. Hainsworth, J.D., Greco, F.A. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clin Lung Cancer 2002, (3 Suppl. 2): S17-S22.
34. Chan, S., Friedrichs, K., Noel, D. et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17: 2341-54.
35. Sjostrom, J., Blomqvist, C., Mouridsen, H. et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35: 1194-201.
36. Nabholtz, J.M., Senn, H.J., Bezwoda, W.R. et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999, 17: 1413-24.
37. Ravdin, P., Erban, J., Overmoyer, B. et al. Phase III comparison of taxotere and paclitaxel in patients with metastatic breast cancer. Eur J Cancer 2003, 5 (Suppl. 1): 32.
38. Mackey, J., Paterson, A., Dirix, L.Y. et al. Final results of the phase III randomized trial comparing docetaxel, doxorubicin, and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002, 21: Abst. 137.
39. Nabholtz, J.M., Falkson, C., Campos, D. et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21: 968-75.
40. O'Shaughnessy, J., Miles, D., Vukelja, S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002, 20: 2812-23.
41. Hutcheon, A.W., Heys, S.D., Sarkar, T.K. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003, 79 (Suppl. 1): S19-S24.
42. Smith, I.C., Heys, S.D., Hutcheon, A.W. et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002, 20: 1456-66.
43. Bear, H.D., Anderson, S., Brown, A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21: 4165-74.
44. Bouzid, K., Vinholes, J., Salas, E. et al. A phase III trial of taxotere and doxorubicin (AT) vs. 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: An interim analysis. Eur J Cancer 2001, 37 (Suppl. 6): S167.
45. Evans, T.R., Yellowlees, A., Foster, E. et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005, 23: 2988-95.
46. Martin, M., Pienkowski, T., Mackey, J. et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352: 2302-13.
47. Roche, H.F.P., Spielman, M. et al. Five-year analysis of the PACS 01 trial: 6 cycles of FEC 100 vs. 3 cycles of FEC 100 followed by 3 cycles of docetaxel for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res Treat 2004, 88 (Suppl. 1): Abst. 27.
48. Roszkowski, K., Pluzanska, A., Krzakowski, M. et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000, 27: 145-57.
49. Georgoulias, V., Papadakis, E., Alexopoulous A. et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicenter trial. Lancet 2001, 357: 1478-84.
50. Schiller, J.H., Harrington, D., Belani, C.P. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346: 92-8.
51. Georgoulias, V., Samonis, G., Papadakis, E. et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small-cell lung cancer: Early results of a randomized trial. Lung Cancer 2001, 34 (Suppl. 4): S47-S51.
52. Georgoulias, V., Ardavanis, A., Agelidou, A. et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J Clin Oncol 2004, 22: 2602-9.
53. Shepherd, F.A., Dancey, J., Ramlau, R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18: 2095-103.
54. Fossella, F.V., DeVore, R., Kerr, R.N. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18: 2354-62.
55. Hanna, N., Shepherd, F.A., Fossella, F.V. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22: 1589-97.
56. Mattson, K.V., Abratt, R.P., ten Velde, G. et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: A multinational randomised phase III study. Ann Oncol 2003, 14: 116-22.
57. Gandara, D.R., Chansky, K., Albain, K.S. et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003, 21: 2004-10.
58. Beer, T.M., Eilers, K.M., Garzotto, M. et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21: 123-8.
59. Berry, W., Dakhil, S., Gregurich, M.A. et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001, 28 (4 Suppl. 15): 8-15.
60. Friedland, D., Cohen, J., Miller, R. Jr. et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999, 26 (5 Suppl. 17): 19-23.
61. Picus, J., Schultz, M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 1999, 26 (5 Suppl. 17): 14-8.
62. Savarese, D.M., Halabi, S., Hars, V. et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001, 19: 2509-16.
63. Oudard, S., Banu, E., Banu, A. et al. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients: A meta-analysis of 3-year overall survival results. J Clin Oncol 2005, 23: 411s.
64. McGuire, W.P., Hoskins, W.J., Brady, M.F. et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996, 23 (5 Suppl. 12): 40-7.
65. Piccart, M.J., Bertelsen, K., James, K. et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000, 92: 699-708.
66. Ozols, R.F., Bundy, B.N., Greer, B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003, 21: 3194-200.
67. du Bois, A., Luck, H.J., Meier, W. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95: 1320-9.
68. Neijt, J.P., Engelholm, S.A., Tuxen, M.K. et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18: 3084-92.
69. Rose, P.G., Blessing, J.A., Ball, H.G. et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003, 88: 130-5.
70. Vasey, P.A., Atkinson, R., Coleman, R. et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001, 84: 170-8.
71. Vasey, P.A., Jayson, G.C., Gordon, A. et al. Phase III randomized trial of docetaxel/carboplatin versus paclitaxel/carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96: 1682-91.
72. Ajani, J., Van Cutsem, E., Moiseyenko, V. et al. Docetaxel, cisplatin, 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MCG): Interim analysis of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003, 22: Abst. 999.
73. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial. Jpn J Clin Oncol 2002, 32: 248-54.
74. Sulkes, A., Smyth, J., Sessa, C. et al. Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994, 70: 380-3.
75. Einzig, A.I., Neuberg, D., Remick, S.C. et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996, 13: 87-93.
76. Roth, A., Mailbach, R., Falk, S. et al. Docetaxel-cisplatin-5FU (TCF) versus Docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2004, 22: 318s.